Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Friday.

In morning trade, the ASX All Ords stock is up 7% to $1.51.

A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

Why is this ASX All Ords stock jumping today?

Investors have been buying the regenerative medicine company's shares following the release of an announcement relating to its flagship Remplir product.

Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.

It was recently given the thumbs up by the US Food & Drug Administration, paving the way for the company to start generating revenue in the country.

Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US$3.5 billion.

What is today's news?

According to the release, the company has added a further eight distributors for Remplir, taking the total number of US distributors signed to 12.

Management notes that the signing of distributors has progressed well ahead of expectations with the company previously only targeting 10 distributors in place by 30 June. It feels that the rapid signing of these new distributors is a testament to the quality of Remplir and the distributors' belief in being able to generate strong sales for the product in the US.

Following these new appointments, the ASX All Ords stock's distributor group collectively covers 21 US states. And with these relationships non-exclusive, the company intends to continue signing additional distributors to expand access to the US market.

'Confident'

Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:

It's very pleasing to see such rapid progress on the expansion of our US distributor network so soon after receiving US FDA clearance in April. We're well ahead of the targets we had set ourselves and expect that to translate to first US Remplir sales this quarter.

Our US team has been working tirelessly leading up to the product launch and we're confident we have the right strategy to drive market penetration of the US. For us, that means a combination of experienced internal employees complemented by a portfolio of distributors who have active sales channels to reach and engage our customers. We expect to grow our portfolio of distributors too.

Following today's strong gain, this ASX All Ords stock is now up almost 300% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man has a surprised and relieved expression on his face.
Healthcare Shares

Bell Potter says this ASX 300 share could rise 80%+

The broker believes an impending announcement could put a rocket under this share if it is positive.

Read more »

Medical ASX share price fall represented by worried looking patient awaiting vaccine injection.
Opinions

Under $100, are CSL shares finally too cheap to ignore?

CSL shares are back below $100 after a brutal sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this giant produce healthy returns or is there more downside to come?

Read more »

a nurse wearing a medical mask prepares a patient for a blood donation in a surgical setting.
Healthcare Shares

What is Morgan's updated view on this red hot ASX healthcare stock?

This company released some exciting results.

Read more »

Falling pills in a blue background.
Healthcare Shares

This ASX healthcare company's profit has rocketed 24%

Expansion into new markets is paying off.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Are these rocketing ASX healthcare shares a must buy?

These companies all rose significantly to start the week.

Read more »

A doctor and an elderly couple sit at a desk and look at a lung scan uploaded.
Healthcare Shares

Why did 4DMedical shares charge higher today, then drop?

The company's key technology has received a big tick.

Read more »

Business woman working from home with stock market chart showing percent change on her laptop screen.
Healthcare Shares

Should I invest $10,000 in CSL shares before the end of May?

This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look.

Read more »